Section Arrow
Quote
CYPH.NASDAQ
- Cypherpunk Technologies Inc.
(Financial Status)
Quotes are at least 15-min delayed:2025/11/15 01:22 EST
Regular Hours
Last
 2.75
+0.99 (+56.25%)
Day High 
3.55 
Prev. Close
1.76 
1-M High
2.54 
Volume 
263.22M 
Bid
2.69
Ask
2.7
Day Low
1.8901 
Open
2.06 
1-M Low
0.393 
Market Cap 
116.14M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 0.73 
20-SMA 0.61 
50-SMA 0.51 
52-W High 3.58 
52-W Low 0.2223 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.58/-0.53
Enterprise Value
116.14M
Balance Sheet
Book Value Per Share
0.10
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
0.04
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ASBPAspire Biopharma Holdings Inc.0.1063+0.0011+1.05%-- 
CYPHCypherpunk Technologies Inc.2.75+0.99+56.25%-- 
IVVDInvivyd2.35+0.58+32.77%-- 
APLTApplied Therapeutics0.2183-0.0517-19.15%-- 
RXRXRecursion Pharmaceuticals4.14-0.19-4.39%-- 
Quotes are at least 15-min delayed：2025/11/15 01:22 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patientswith colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.